- Policy
- MFDS orders minimized use of varenicline
- by Lee, Tak-Sun Jul 12, 2021 05:58am
- The Ministry of Food and Drug Safety ordered minimized use of the smoking-cessation treatment, ‘varenicline.’ The measure was announced 3 weeks after safety investigations had started for the products, from the 22nd of last month. The MFDS announced that it has issued a Dear Healthcare Professional Letter regarding the precautions to ta
- Policy
- Ultra-high-priced drugs(Kymriah) need coverage within a year
- by Lee, Jeong-Hwan Jul 11, 2021 07:05pm
- In order to commercialize high-tech biopharmaceuticals, which are evaluated as ultra-high-priced new drugs, it has been argued that a policy to recognize insurance benefits should follow beyond Expedited Review within at least a year of approval. It is pointed out that although the enactment of the Advanced Regenerative Bio Act in 2019 est
- Company
- Huons has secured domestic rights to Sputnik Light
- by Lee, Seok-Jun Jul 11, 2021 07:03pm
- Huons said on the 7th that it has secured exclusive rights to domestic licenses and sales of Russia's one-shot vaccine Sputnik Light. Sputnik Light will be produced from Huons Global Consortium starting from second half of this year. It was developed by Gamaleya Research Institute of Epidemiology and Microbiology. It is a one-shot vacci
- Policy
- Early supply of Pfizer in exchange for a vaccine with Israel
- by Kim, Jung-Ju Jul 11, 2021 07:01pm
- The Minister of Health and Welfare, Kwon Deok-chul signed a vaccine swap agreement today (6th), which will receive 700,000 pfizer vaccines from the Israeli government in July and return them sequentially from September to November. Recently, the Israeli government was looking for ways to make effective use of the vaccine, with some of the
- Policy
- Bayer applies for approval of ‘Finerenone’ in Korea
- by Lee, Tak-Sun Jul 9, 2021 05:57am
- A groundbreaking new drug developed by Bayer is undergoing review for approval in Korea. The drug is known to inhibit disease progression in chronic kidney disease (CKD) patients with diabetes. According to industry sources on the 8th, Bayer applied for the approval of its ‘finerenone (Kerendia tab)’ to the Ministry of Food and Drug
- Company
- Researchers find COVID-19 Txs more effective than remdesivir
- by Kim, Jin-Gu Jul 9, 2021 05:56am
- A Korean research team of the Korea Advanced Institute of Science and Technology (KAIST) discovered new drug candidates for the treatment of COVID-19. Some of the candidates are expected to have a better effect than the currently approved remdesivir (product name: Veklury). On the 8th, the joint research team of Sang-yup Lee, Distinguished Pr
- Company
- Jeil's anti-cancer drug business is doing well
- by Nho, Byung Chul Jul 8, 2021 05:59am
- It is noteworthy that Jeil is investing in expanding the lineup of anticancer drugs and research and development in related fields. Jeil, who entered his 33rd year of anti-cancer drug business, has a strategic relationship with Kyowa Kirin and Taiho in Japan and is making efforts to distribute original anti-cancer drugs. When the new
- InterView
- Takeda, “Alunbrig improved both OS and QoL”
- by Jul 8, 2021 05:58am
- Medical Science Liaisons (MSLs) in Medical Affairs of pharmaceutical companies act as a ‘bridge’ between healthcare professionals and companies. They gather the unmet needs of HCPs and establish strategies for new drugs to address such needs. MSLs also deliver academic data and expertise based on clinical grounds in compliance with local regul
- Company
- Chong Kun Dang loses 1st substance patient suit on ‘Xarelto
- by Kim, Jin-Gu Jul 8, 2021 05:58am
- Chong Kun Dang has lost its first trial targeting the substance patent of Bayer’s new oral anticoagulant (NOAC) ‘Xarelto(rivaroxaban).’ Whether Chong Kun Dang will modify its strategy to preoccupy the market through a release of its generic before substance patent expiry due to this ruling is gaining attention. On the 6th, the Intel
- Company
- GC Pharma, the most likely company to produce Covivak
- by Nho, Byung Chul Jul 8, 2021 05:58am
- Chumakov Institute recently visited Andong Animal Cell Verification Support Center. Russia's Covivak is likely to be produced in domestic CMOs. According to industries, MPC, which is a South Korean corporation to introduce Covivak, recently signed a contract with Pharm Bio-tech, a Russian company that has rights to produce and publish in
